CU Cancer Center

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

Written by OncLive | July 28, 2020

Paul A. Bunn, Jr, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado and a 2014 Giant of Cancer Care® in Lung Cancer, highlights encouraging data with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-mutant non–small cell lung cancer (NSCLC).